This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Teva Pharmaceutical Industries Ltd.
Drug Names(s): bendamustine hydrochloride, SDX-105, Ribomustin, Levact (EU), SyB L-0501, Treakisym (Japan), Symbenda (Singapore), Innomustine (Taiwan)
Description: Treanda (bendamustine hydrochloride) is a nitrogen mustard alkylating agent originally developed in East Germany for the treatment of hematological malignancies.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
Salmedix and Fujisawa
Treanda was developed by Fujisawa Deutschland. In May 2003, Salmedix signed a license agreement with Fujisawa Deutschland GmbH, or F-DE, for exclusive rights in the U.S. and Canada to utilize F-DE's proprietary information to develop, manufacture and market Treanda.
Astellas and Fujisawa
On April 1, 2005, Astellas Pharma was formed from a merger between Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical.
Cephalon and Salmedix
On May 12, 2005, Cephalon announced that it signed a definitive merger agreement under which it will acquire all of the outstanding capital stock of Salmedix for approximately $160 million cash; Cephalon is required to pay an additional $40 million of cash payments upon the achievement of certain regulatory milestones.
SymBio and Astellas
In December 2005, SymBio Pharmaceuticals licensed in the Japanese rights for bendamustine...See full deal structure in Biomedtracker
Partners: Astellas Pharma, Inc. Mundipharma International Limited SymBio Pharmaceuticals Ltd. Eisai Co., Ltd. H. Lundbeck A/S InnoPharmax Inc.
Additional information available to subscribers only: